A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Study Number:E4512
IRB Number:669503
Trial Type:Oncology - Pulmonary
Trial Status:Open to Accrual
Date Posted:
Principal Investigator:Mei Tang, MD
Contact Name:Steven Schmitt
Phone:(443) 849-3592
Fax:(443) 849-3777

For more details on this study, please refer to the Clinicaltrials.gov website at the link below:


IMPORTANT Visitor Policy Changes

Recent Stories
In the Media